Blood-based biomarkers for Alzheimer's disease?
نویسندگان
چکیده
منابع مشابه
Blood-based protein biomarkers for diagnosis of Alzheimer disease.
OBJECTIVE To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). DESIGN Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker and clinical pathology data. SETTING General community-based, prospective, longitudinal study of aging. PARTICIPANTS A total of 754 healthy individuals serving as controls and 207 participants with AD from the Au...
متن کاملMethodology for discovery of Alzheimer's disease blood-based biomarkers.
Alzheimer's disease (AD) is a degenerative brain disorder. The disease also affects peripheral tissue such as peripheral blood mononuclear cells (PBMCs). Delineating biochemical alterations in AD blood constituents may possibly allow the identification of accessible footprints that reflect degenerative processes within the central nervous system. Here, we describe an integrated methodology for ...
متن کاملDeveloping novel blood-based biomarkers for Alzheimer's disease.
Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association a...
متن کاملAmelioration of Symptoms and Biomarkers of Alzheimers Disease by Physical Exercise
Physical exercise advantages have been manifested in several neurodegenerative and/or neuropsychiatric disorders implying that these, largely non-invasive, non-pharmacologic interventions, ought to be examined closely in the Alzheimer’s disease (AD) and other dementias context. Thus, according to the tenets of an increasingly broad consensus, preventative and interventional agents for AD and de...
متن کاملBlood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology
The complexity of Alzheimer's disease (AD) and its long prodromal phase poses challenges for early diagnosis and yet allows for the possibility of the development of disease modifying treatments for secondary prevention. It is, therefore, of importance to develop biomarkers, in particular, in the preclinical or early phases that reflect the pathological characteristics of the disease and, moreo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Drug Discovery
سال: 2014
ISSN: 1474-1776,1474-1784
DOI: 10.1038/nrd4323